Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
BioLife Solutions manufactures and supplies biopreservation media, cold chain management systems, and cryogenic storage equipment for cell and gene therapy developers, biobanks, and regenerative medicine companies. The company serves a niche but growing market supporting the clinical and commercial manufacturing of advanced therapies, with products including CryoStor freeze media, HypoThermosol shipping solutions, and evo cold chain shippers. The 42.6% revenue decline reflects significant headwinds in the cell and gene therapy sector as multiple clinical programs have been delayed or discontinued industry-wide.
BioLife generates revenue through a razor-razorblade model where initial equipment sales (freezers, shippers) create installed base for recurring consumable media purchases. The company's biopreservation media products are validated and integrated into customer manufacturing processes, creating high switching costs once adopted in clinical trials or commercial production. Pricing power derives from regulatory validation requirements - once a preservation protocol is approved in a clinical trial, customers cannot easily substitute products without repeating expensive validation studies. Gross margins of 65.3% reflect the specialized nature of products and limited direct competition in certain product categories.
Cell and gene therapy sector funding and clinical trial activity - venture capital investment levels and biotech IPO market directly drive customer demand
FDA approvals and commercial launches of CAR-T and gene therapies - each new therapy approval creates demand for preservation media and cold chain logistics
Customer manufacturing scale-up announcements - transition from clinical to commercial manufacturing drives 10-100x volume increases in media consumption
M&A activity in biopreservation sector - consolidation among suppliers or customer base impacts competitive dynamics and growth outlook
Cell and gene therapy sector maturation risk - if approved therapies fail to demonstrate cost-effectiveness or achieve commercial success, the entire sector growth thesis weakens and demand for biopreservation products plateaus below expectations
Regulatory pathway changes - FDA modifications to manufacturing requirements or preservation validation standards could obsolete existing product lines or require expensive reformulation and revalidation
Technology disruption - alternative preservation methods (e.g., room temperature stabilization technologies) could reduce or eliminate need for cryogenic storage and cold chain logistics
Large life sciences suppliers (Thermo Fisher, Merck) expanding into biopreservation through internal development or acquisition, leveraging existing customer relationships and broader product portfolios
Customer vertical integration - large therapy manufacturers developing proprietary preservation solutions in-house to reduce costs and maintain supply chain control
Pricing pressure as market matures - currently limited competition allows premium pricing, but market growth will attract new entrants and commoditize certain product categories
Negative operating cash flow and -24.5% net margin create cash burn requiring eventual capital raise if profitability not restored - dilution risk to existing shareholders
Goodwill and intangible assets from prior acquisitions may face impairment risk if revenue recovery takes longer than expected or customer attrition accelerates
moderate - While healthcare spending is relatively defensive, BioLife's customers are primarily venture-backed biotechnology companies and the cell/gene therapy sector is highly sensitive to risk capital availability. During economic downturns, biotech funding contracts sharply, causing clinical trial delays and reduced manufacturing activity. However, once therapies reach commercial stage, demand becomes more stable as patient treatment is less economically sensitive. The current revenue decline reflects sector-specific funding challenges rather than broad economic weakness.
High sensitivity through customer financing channel. Rising interest rates significantly impact BioLife's biotech customers by: (1) reducing venture capital and IPO activity that funds clinical trials, (2) increasing cost of capital for unprofitable therapy developers, forcing program prioritization or delays, and (3) making speculative growth investments less attractive relative to fixed income. The 2022-2024 rate hiking cycle directly contributed to biotech funding drought that drove BioLife's revenue decline. Lower rates would stimulate customer funding and accelerate therapy development timelines.
Minimal direct credit exposure given strong balance sheet with 4.66x current ratio and only 0.06 debt/equity. However, indirect credit exposure exists through customer base - if biotech customers face funding difficulties or bankruptcies, accounts receivable risk increases and future order flow declines. The company's customers often operate with negative cash flow and depend on capital markets access.
growth - The stock attracts investors betting on long-term cell and gene therapy sector expansion despite near-term profitability challenges. The 14.5x price/sales multiple despite negative margins indicates market is valuing future earnings potential rather than current financial performance. Investors are typically willing to tolerate volatility and negative cash flow in exchange for exposure to high-growth healthcare innovation theme. Current 21% one-year decline has likely shaken out momentum investors, leaving more patient growth-oriented holders.
high - Small-cap healthcare stock with $1.1B market cap, negative profitability, and customer base concentrated in volatile biotech sector creates significant price volatility. Stock moves sharply on quarterly results, customer announcements, and broader biotech sector sentiment shifts. Beta likely exceeds 1.5 relative to broader market given sector-specific risks and limited analyst coverage typical of small-cap names.